Fundraising FoxVedanta Biosciences
Cambridge, US · Delaware corporation · 9 known investors
Find your way into Vedanta Biosciences
Sign up to see every warm intro you have to Vedanta Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Vedanta Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Vedanta Biosciences is a clinical-stage biotech developing Live Biotherapeutic Products (LBP) based on defined consortia of bacteria to treat serious gastrointestinal diseases, with an initial focus on preventing recurrent Clostridium difficile infection. Its oral therapies target gut dysbiosis-driven conditions.
Founders & leadership
BO
Bernat OlleChief Executive Officer, founder, Board of DirectorsExecutive officer and director at Vedanta Biosciences, a clinical-stage biotech company developing live biotherapeutic products for gastrointestinal and infectious diseases. Olle has expertise in biotech, microbiome science, and life sciences entrepreneurship.
DC
Daniel CoutoChief Operating OfficerDaniel Couto is Chief Operating Officer of Vedanta Biosciences and brings over 30 years of biopharmaceutical manufacturing and operations experience, including prior roles as SVP of Manufacturing and Operations at ContraFect Corporation and VP of Commercial Manufacturing Operations at Merck Sharp Dohme Biologics UK. He holds a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute.
MM
Mark MullikinChief Financial Officer2021–2025Mark Mullikin is an executive with three decades of experience leading teams at both early-stage and established companies, with background in capital markets and investment management.
JS
Jeffrey SilberChief Medical Officer2020–2026Jeffrey Silber held senior leadership roles in drug development across multiple therapeutic areas at Merck, including involvement in preclinical through commercial lifecycle management and participation in cross-divisional strategy committees.
CV
Christopher ViehbacherNamed on SEC filing
Board
JL
CS
Charles SherwoodBoard director
MH
NT
CL
Curt LaBelleBoard director
BS
Bennett ShapiroBoard director
TI
Investors · 9
AMR Action Fundlisted by AMR Action FundBostonvia Martin Heidecker · board
How we know: AMR Action Fund's portfolio page · a partner's Signal profile · board seat on SEC Form D · funding news · Not right? Tell us
Colorcon Ventureslisted by Colorcon Ventures$500K – $2.5M
How we know: Colorcon Ventures's portfolio page · Not right? Tell us
K2 HealthVentureslisted by K2 HealthVenturesBoston
How we know: K2 HealthVentures's portfolio page · Not right? Tell us
Salica Investmentslisted by Salica InvestmentsLondon
How we know: the VCSheet dataset · Not right? Tell us
Seventure Partnerslisted by Seventure PartnersParis
How we know: Seventure Partners's portfolio page · Not right? Tell us
BNP Paribasreported
How we know: funding news · Not right? Tell us
BNP Paribas Asset Management EuropereportedParis
How we know: funding news · Not right? Tell us
Global Health Investment FundreportedNew York
How we know: a partner's Signal profile · Not right? Tell us
Funding
SEC filings, press & company announcements$300.3M disclosed across 5 rounds · 2018–2026
- $60MraisedAug 2026 · 3 sourcesSource ↗
▶$118.5MraisedAug 2024 · 25 investors · BiotechnologyRule 506(b)
▶$118.5MraisedAug 2024 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John LaMattinaDirector
- Charles SherwoodDirector
- Susan DillonDirector
- Martin HeideckerDirector
- Neil TiwariDirector
- Curt LaBelleDirector
- Daniel CoutoExecutive Officer
- Bernat OlleExecutive Officer, Director
- Mark MullikinExecutive Officer
- Bennett ShapiroDirector
- Troy IgnelziDirector
- Jeffrey SilberExecutive Officer
- Offering amount
- $118.5M
- Amount sold
- $118.5M
- Sales commissions
- $400K
- Placement agents
- FJS Consultants Limited
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$68.4MraisedAug 2021 · 18 investors · BiotechnologyRule 506(b)
▶$68.4MraisedAug 2021 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher ViehbacherDirector
- Bernat OlleExecutive Officer, Director
- Susan DillonDirector
- Troy IgnelziDirector
- John L LaMattinaDirector
- Daniel CoutoExecutive Officer
- Bharatt ChowriraDirector
- Mark MullikinExecutive Officer
- Bennett M ShapiroDirector
- Jeffrey SilberExecutive Officer
- Offering amount
- $75M
- Amount sold
- $68.4M
- Sales commissions
- $400K
- Placement agents
- FJS Consultants Limited
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedSep 2019 · 4 investors · Other Health CareRule 506(b)
▶$8MraisedSep 2019 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Susan DillonDirector
- Bharatt ChowriraDirector
- Bennett M. ShapiroDirector
- John L. LaMattinaDirector
- Christopher ViehbacherDirector
- Bernat OlleExecutive Officer, Director
- Offering amount
- $16.6M
- Amount sold
- $8M
- Sales commissions
- $160K
- Placement agents
- China eCapital Partners, LLC
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$45.4MraisedMay 2019 · 13 investors · Other Health CareRule 506(b)
▶$45.4MraisedMay 2019 · 13 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Bernat OlleExecutive Officer, Director
- Bharatt ChowriraDirector
- Bennett M. ShapiroDirector
- John L. LaMattinaDirector
- Christopher ViehbacherDirector
- Susan DillonDirector
- Offering amount
- $50M
- Amount sold
- $45.4M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Vedanta Biosciences went on to found or lead other companies.
Related companies · 4
Enanta PharmaceuticalsEnanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule therapeutics using chemistry-based research to treat diseases with high unmet medical need. Its work has contributed to hepatitis C virus combination therapies, and its pipeline includes programs in areas such as respiratory syncytial virus (RSV).
VintaBioVintaBio provides viral vector manufacturing for clinical and commercial gene therapies, using a single-stream process (VintaProcess) to produce high-yield, high-purity vectors. It offers end-to-end services from discovery through final delivery for cell and gene therapy developers.
VandaVanda is a biopharmaceutical company that develops new medicines, using genetics and genomics to guide drug discovery, clinical trials, and commercial positioning of its compounds. It works to advance novel approaches for delivering these medicines to patients.
ProximaProxima is a biotech company developing proximity therapeutics through a drug discovery engine and a structural proteomics data platform.
Companies working in the same space as Vedanta Biosciences.
In the news
Frequently asked questions
- What does Vedanta Biosciences do?
- Vedanta Biosciences is a clinical-stage biotech developing Live Biotherapeutic Products (LBP) based on defined consortia of bacteria to treat serious gastrointestinal diseases, with an initial focus on preventing recurrent Clostridium difficile infection. Its oral therapies target gut dysbiosis-driven conditions.
- Who founded Vedanta Biosciences?
- Vedanta Biosciences was founded by Bernat Olle.
- Who are Vedanta Biosciences's investors?
- Vedanta Biosciences's investors include AMR Action Fund, Colorcon Ventures, K2 HealthVentures, Salica Investments, Seventure Partners, BNP Paribas, BNP Paribas Asset Management Europe, Global Health Investment Fund and 1 more.
- How much funding has Vedanta Biosciences raised?
- Vedanta Biosciences has disclosed $300.3M raised across 5 rounds.
- Where is Vedanta Biosciences headquartered?
- Vedanta Biosciences is headquartered in Cambridge, US.